Therapy directed against SLE activity with hydroxychloroquine has proven to be effective in the primary prevention of thrombotic events in patients with SLE and cardiovascular risk factors by playing a role in lowering cholesterol, inhibiting platelet aggregation, better glycemic control, and insulin resistance [2,5,11]. This evidence concerns the gene INS and systemic lupus erythematosus.